Аннотация:
Background: Chronic acrodermatitis continua of Hallopeau (ACH) is a rare form of pustular psoriasis predominantly affecting the distal phalanges of the fingers and toes. The disease manifests by pustular rash with marked infiltration, fissures, and often results into severe dystrophy of nail plates. ACH is refractory to most of psoriasis standard of care (SOC) therapies. Objective: The objective of this study is to assess the prospects of secukinumab therapy of ACH based on current clinical observation. Methods: We observed a female patient with ACH. Number of SOC treatments were applied in that case including local PUVA therapy, systemic retinoids, methotrexate, and biologic agents. Result: Secukinumab, a IL-17 inhibitor, demonstrated pronounced clinical effect in the case of ACH refractory to other SOC therapies. Conclusion: IL-17 inhibition provided by secukinumab was linked to clinically meaningful improvement in the heavily pretreated ACH. Further exploration and clinical studies
Ключевые слова:
Acrodermatitis continua of Hallopeau; Anti IL-17A therapy; Apremilast; Phosphodiesterase-4; Secukinumab
apremilast; biological product; infliximab; interleukin 17; methotrexate; retinoid; secukinumab; acrodermatitis continua; adult; Article; case report; clinical article; clinical observation; diarrhea; disease severity; distal phalanx; drug dose escalation; female; histopathology; human; hyperkeratosis; nail dystrophy; nausea; onycholysis; physical examination; prospective study; pustular psoriasis; treatment resistant acrodermatitis continua; ultraviolet A radiation
Smirnova L. M.
Vertieva E. Yu. Ekaterina Yuryevna 1984-
Olisova O. Yu. Ol`ga Yuryevna 1957-
Anpilogova E. M. Ekaterina Mikhaylovna 1993-
Смирнова Л. М.
Вертиева Е. Ю. Екатерина Юрьевна 1984-
Олисова О. Ю. Ольга Юрьевна 1957-
Анпилогова Е. М. Екатерина Михайловна 1993-
Outcomes of various types of therapy in patients with treatment-resistant acrodermatitis continua of hallopeau
Текст визуальный непосредственный
Biologics: Targets and Therapy
Vol.13 P. 83-87
2019
Статья
Acrodermatitis continua of Hallopeau Anti IL-17A therapy Apremilast Phosphodiesterase-4 Secukinumab
apremilast biological product infliximab interleukin 17 methotrexate retinoid secukinumab acrodermatitis continua adult Article case report clinical article clinical observation diarrhea disease severity distal phalanx drug dose escalation female histopathology human hyperkeratosis nail dystrophy nausea onycholysis physical examination prospective study pustular psoriasis treatment resistant acrodermatitis continua ultraviolet A radiation
Background: Chronic acrodermatitis continua of Hallopeau (ACH) is a rare form of pustular psoriasis predominantly affecting the distal phalanges of the fingers and toes. The disease manifests by pustular rash with marked infiltration, fissures, and often results into severe dystrophy of nail plates. ACH is refractory to most of psoriasis standard of care (SOC) therapies. Objective: The objective of this study is to assess the prospects of secukinumab therapy of ACH based on current clinical observation. Methods: We observed a female patient with ACH. Number of SOC treatments were applied in that case including local PUVA therapy, systemic retinoids, methotrexate, and biologic agents. Result: Secukinumab, a IL-17 inhibitor, demonstrated pronounced clinical effect in the case of ACH refractory to other SOC therapies. Conclusion: IL-17 inhibition provided by secukinumab was linked to clinically meaningful improvement in the heavily pretreated ACH. Further exploration and clinical studies